secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001736730-26-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 FY2025 net loss $80.4M; cash runway into 2028, GSK deal, SYNGAP1 progress
-------------------------------------------------------------------------------

- Net loss of $80.4M in FY2025 vs $51.8M in FY2024, driven by $29.8M non-cash loss on derivative tranche liability.
- Cash and equivalents $109.5M (Dec 31, 2025), up from $64.0M; cash runway extended into 2028.
- GSK collaboration: $17.5M upfront, up to $440M in milestones plus tiered royalties for ASO candidates in neurodegenerative and kidney diseases.
- GLP tox studies for CMP-002 ongoing; global Phase 1/2 trial in SYNGAP1 patients expected as early as H2 2026.
- Paused development of CMP-001 and exploring partnership opportunities for that program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/0001736730-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/camp-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001736730-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer